Xianqi Kong

Discovery andCharacterization of RP04340 : A Highly Potent and OrallyActive Pan-KRAS PROTAC Degrader

Abstract Targeting diverse KRAS mutations with a single agent remains a significant challenge in oncology. Here, we report the discovery and characterization of RP04340, a potent and orally bioavailable pan-KRAS PROTAC degrader. Starting with a structure-based pan-KRAS inhibitor...